雷替曲塞单药二线治疗晚期大肠癌疗效观察

目的 评价雷替曲塞单药二线治疗晚期大肠癌的疗效及安全性.方法 对28例经过一线化疗之后出现复发或进展的晚期结直肠癌患者采用雷替曲塞单药方案化疗.雷替曲塞3 mg/m2,d1静脉输注15 min,每三周重复1次.至少进行3周期.观察疗效、不良反应,并随访观察中位无疾病进展生存期(MPFS)、一年生存率.结果 28例患者,总有效率28.6%,中位无疾病进展生存期(MPFS)6.5个月,一年生存率42.9%.最常见不良反应是粒细胞减少、胃肠道反应和转氨酶升高,但副反应可控.结论 雷替曲塞二线治疗晚期复发转移结直肠癌疗效肯定,耐受性好.

The observation of raltitrexed as Second-line chemotherapy for advanced colorectal cancer

Objective To evaluate the efficacy and toxicity of raltitrexed as Second-line chemotherapy in the treatment of advanced colorectal cancer. Methods 28 patients with advanced coloreetal cancer who had received first-line therapy but had relapsed or progressed were given 3 mg/m^2 of raltitrexed and repeated every 3 weeks, All patients received three cycles of chemotherapy at least. We evaluated the efficacy, toxicity, median progression-free survival（MPFS） and one year survival rate. Results In 28 patients, the total effective rate was 28. 6%, median progression-free survival（MPFS） was 6. 5 months and one year survival rate was 42. 9%. The major toxicities included neutropenia, gastrointestinal reaction and the elevation of liver enzymes. Conclusion Raltitrexed as second-line chemotherapy in treatment of refractory or metastatic eolorectal cancer is effective and well tolerated.